Background: The relationship between C-reactive protein (CRP) and proteinuria is not known. Methods: We examined 20,077 screenees (men: 52.4%) of the Okinawa General Health Maintenance Association (OGHMA) registry who were examined between 2004 and 2006. Cross-sectional and longitudinal relationships between CRP and dipstick proteinuria were examined. The OGHMA central laboratory measured creatinine and CRP levels using an autoanalyzer (normal: <0.30 mg/dl). The glomerular filtration rate was estimated using the Japanese formula. Results: The prevalence of dipstick-positive proteinuria increased from 5.2% in screenees with a low CRP level of <0.10 mg/dl to 12.3% in those with high CRP levels (0.30–0.90 mg/dl). The CRP values did not affect the mean (SD) estimated glomerular filtration rate: 76.9 (13.7) with low CRP and 76.4 (15.1) with high CRP levels. We examined the relationship between baseline CRP and the development of proteinuria among subjects screened in 2004. Of 8,315 subjects without proteinuria examined again by 2006, 370 (4.4%) had developed proteinuria. The odds ratio (95% CI) for high CRP levels (0.30–0.90 mg/dl; reference CRP: <0.10 mg/dl) was 1.433 (1.013–2.028; p = 0.0422) after adjusting for multivariate variables, suggesting that CRP is closely associated with the prevalence and incidence of proteinuria. Conclusion: A prospective study on the development of proteinuria among those with high CRP levels is warranted. Screenees with high CRP levels may need to be followed up carefully despite the absence of traditional risk factors for proteinuria.

1.
Iseki K, Tozawa M, Yoshi S, et al: Serum C-reactive protein and risk of death in chronic dialysis patients. Nephrol Dial Transplant 1999;14:1956–1960.
2.
Zimmermann J, Herrlinger S, Pruy A, et al: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55:648–658.
3.
Nakai S, Wada A, Kitaoka T, et al: An overview of regular dialysis treatment in Japan (as of 31 December 2004). Therap Apher Dial 2006;10:476–497.
4.
Iseki K: Chronic kidney disease in Japan. Int Med 2008;26:13–17.
5.
Konta T, Hao Z, Abiko H, et al: Prevalence and risk factor analysis of microalbuminuria in Japanese general population: the Takahata study. Kidney Int 2006;70:751–756.
6.
Nakamura M, Onoda T, Itai K, et al: Association between serum C-reactive protein levels and microalbuminuria: a population-based cross-sectional study in northern Iwate, Japan. Int Med 2004;43:919–925.
7.
Iseki K: Chronic kidney disease in Japan: from early predictions to current facts. Nephron Clin Pract 2008;110:268–272.
8.
Iseki K: The Okinawa screening program. J Am Soc Nephrol 2003;14(suppl 2):S127–S130.
9.
Iseki K: Screening for renal disease: what can be learned from the Okinawa experience. Nephrol Dial Transplant 2006;21:839–843.
10.
Matsuo S, Imai E, Horio M, et al: Revised equations for estimating glomerular filtration rate from serum creatinine in Japan. Am J Kidney Dis 2009;53:982–992.
11.
Iseki K, Iseki C, Ikemiya Y, et al: Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int 1996;49:800–805.
12.
Iseki K, Ikemiya Y, Iseki C, et al: Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003;63:1468–1474.
13.
Ruggenenti P, Perticucci E, Cravedi P, et al: Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 2008;19:1213–1224.
14.
Fliser D, Wagner KK, Loos A, et al: Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005;4:1135–1140.
15.
Sarnak MJ, Levey AS, Schoolwerth AC, et al: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154–2169.
16.
Go AS, Chertow GM, Fan D, et al: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–1305.
17.
Weiner DE, Tighiouart H, Elsayed EF, et al: Inflammation and cardiovascular events in individuals with and without chronic kidney disease. Kidney Int 2008;73:1406–1412.
18.
Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990;38:384–394.
19.
Imai E, Horio M, Yamagata K, et al: GFR decline rate in Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res 2008;31:433–442.
20.
Imai E, Horio M, Iseki K, et al: Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol 2007;11:156–163.
21.
Tozawa M, Iseki C, Tokashiki K, et al: Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults. Hypertens Res 2007;30:937–943.
22.
Ninomiya T, Kiyohara Y, Kubo M, et al: Metabolic syndrome and CKD in a general Japanese population: the Hisayama study. Am J Kidney Dis 2006;48:383–391.
23.
Kambham N, Markowitz GS, Valeri AM, et al: Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001;59:1498–1509.
24.
Wang Y, Chen X, Song Y, et al: Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int 2008;73:19–33.
25.
Krikken JA, Lely AT, Bakker SJ, et al: The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int 2007;71:260–265.
26.
Yamagata K, Ishida K, Sairenchi T, et al: Risk factors for chronic kidney diseases in a community-based population: a 10-year follow-up study. Kidney Int 2007;71:159–166.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.